Two Convenient Submission Methods

Cancer Genetics Research We Publish

Expert Review by Cancer Genetics Specialists

Your cancer biomarker research will be evaluated by leading pathophysiology experts who understand the nuances of molecular mechanisms, disease pathways, and biomarker validation. Our peer review process ensures rigorous assessment while providing constructive feedback to strengthen your manuscript.

Our reviewers assess manuscripts based on scientific rigor, novelty of biomarker findings, appropriateness of molecular techniques, statistical validity, reproducibility of methods, and potential impact on understanding cancer pathophysiology. We prioritize constructive criticism that helps authors improve their research presentation while maintaining high publication standards.

Submission Requirements for Cancer Genetics Studies

To ensure efficient processing of your biomarker research, please prepare the following materials before beginning your submission:

Manuscript Components: Your cancer genetics manuscript should include a structured abstract (250 words maximum), 5-8 keywords relevant to molecular pathology and biomarker research, comprehensive introduction establishing the pathophysiological context, detailed methods section describing molecular techniques and statistical analyses, results with appropriate figures and tables, discussion interpreting findings within the cancer genetics literature, and conclusions highlighting translational implications.

Data Transparency: JCGB strongly encourages deposition of raw genomic data, proteomics datasets, and bioinformatics code in appropriate repositories. For biomarker studies, provide access to underlying data supporting sensitivity/specificity claims. Include repository accession numbers (GEO, SRA, ProteomeXchange) in your manuscript. If data cannot be shared due to patient privacy concerns, provide a clear data availability statement explaining access procedures.

Ethics Documentation: All cancer genetics research involving human samples must include IRB approval documentation, informed consent procedures, and compliance with HIPAA or equivalent regulations. Animal studies require IACUC approval and adherence to ARRIVE guidelines. For biomarker validation studies using clinical samples, describe patient recruitment, inclusion/exclusion criteria, and sample collection protocols in detail.

Reporting Standards: Follow discipline-specific reporting guidelines appropriate to your study design. Biomarker validation studies should follow REMARK guidelines, diagnostic accuracy studies should use STARD, systematic reviews should follow PRISMA, and animal studies should comply with ARRIVE. Include completed checklists as supplementary files to expedite peer review.

Figure Quality: Molecular biology figures including Western blots, immunohistochemistry images, flow cytometry plots, and microscopy images must be high-resolution (minimum 300 DPI) in TIFF or PNG format. Provide original, unprocessed images as supplementary files. For biomarker ROC curves and survival analyses, ensure axes are clearly labeled with appropriate statistical annotations.

Understanding Our Acceptance Rate

JCGB maintains a 59% acceptance rate, reflecting our commitment to publishing high-quality cancer genetics research while supporting authors through the peer review process. This acceptance rate indicates that we value rigorous science and provide constructive feedback to help strengthen manuscripts that show promise but require revision.

Manuscripts are typically declined when they fall outside our scope (clinical treatment outcomes rather than molecular mechanisms), lack sufficient methodological rigor for biomarker validation, present findings without adequate statistical power, or fail to advance understanding of cancer pathophysiology. Our editors provide detailed feedback even for declined manuscripts, often suggesting alternative journals or recommending additional experiments to strengthen the work.

For cancer genetics researchers, this acceptance rate means your biomarker discovery studies, pathway analyses, and mechanistic investigations have a strong chance of publication if they meet scientific standards and contribute novel insights to understanding cancer at the molecular level. We encourage submission of well-designed studies even if results are negative or unexpected-such findings are valuable for the cancer genetics community.

Article Processing Charges & Waivers

As an open access journal, JCGB charges an Article Processing Charge (APC) to cover peer review coordination, editorial production, hosting infrastructure, and indexing services. This ensures your cancer genetics research is immediately accessible worldwide without subscription barriers.

The standard APC for accepted manuscripts is clearly listed on our website. However, we recognize that funding availability varies across institutions and career stages. JCGB offers APC waivers and discounts for early-career investigators, researchers from low- and middle-income countries, and authors without institutional funding support. Waiver requests are evaluated confidentially and do not influence editorial decisions.

To request an APC waiver, indicate your eligibility during the submission process and provide brief justification. Our editorial office will respond within 48 hours. We are committed to ensuring that financial constraints do not prevent publication of important cancer biomarker research that advances understanding of disease mechanisms.